David A Braun

List of Publications by Year
in descending order

44	3,025	236925	330143
papers	citations	25 h-index	37 g-index

46	46	46	3623
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncology, The, 2022, 23, 172-184.	10.7	58
2	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	6.4	40
3	Tumor-Infiltrating T Cells â€" A Portrait. New England Journal of Medicine, 2022, 386, 992-994.	27.0	10
4	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical Cancer Research, 2022, 28, 748-755.	7.0	9
5	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	7.0	12
6	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology, 2022, 40, 2913-2923.	1.6	40
7	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature, 2022, 605, 532-538.	27.8	70
8	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. Journal of Clinical Oncology, 2022, 40, 4549-4549.	1.6	0
9	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. Journal of Clinical Oncology, 2022, 40, 4531-4531.	1.6	3
10	Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2622-2622.	1.6	0
11	Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.. Journal of Clinical Oncology, 2022, 40, e16521-e16521.	1.6	0
12	Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.. Journal of Clinical Oncology, 2022, 40, e16522-e16522.	1.6	0
13	Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.. Journal of Clinical Oncology, 2022, 40, 6520-6520.	1.6	1
14	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	7.0	12
15	Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 244-256.	27.6	138
16	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	7.0	49
17	Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Molecular and Cellular Proteomics, 2021, 20, 100133.	3.8	32
18	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84

#	Article	IF	Citations
19	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell, 2021, 39, 649-661.e5.	16.8	263
20	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2021, 39, 4583-4583.	1.6	0
21	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	16.8	230
22	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics, 2021, 20, 1454-1461.	4.1	6
23	CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research, 2021, 27, 4025-4035.	7.0	51
24	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 166, 103463.	4.4	3
25	Beyond conventional immune-checkpoint inhibition â€" novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214.	27.6	179
26	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 1815.	7.1	40
27	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus, 2020, 6, 37-40.	3.1	6
28	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 372-381.	5.4	59
29	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	1.6	109
30	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nature Biotechnology, 2020, 38, 199-209.	17.5	324
31	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). Journal of Clinical Oncology, 2020, 38, 4240-4248.	1.6	69
32	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	30.7	488
33	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer, 2020, 135, 203-210.	2.8	50
34	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genetics in Medicine, 2020, 22, 1366-1373.	2.4	40
35	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	3.4	47
36	OTHR-04. INCIDENCE AND SURVIVAL OUTCOMES IN UROTHELIAL CARCINOMA BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i18-i19.	0.7	0

#	Article	IF	Citations
37	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	7.0	50
38	What was old is new again: learning from the modern master clinician. Clinical Teacher, 2019, 16, 274-276.	0.8	0
39	Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncology, 2019, 5, 1631.	7.1	166
40	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	12.8	139
41	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	7.0	80
42	A Disturbing Decline. New England Journal of Medicine, 2019, 380, 2257-2262.	27.0	2
43	Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine, 2018, 10, 87.	8.2	51
44	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.0	8